Daewoong Pharmaceutical has officially launched its botulinum toxin product, NUCEIVA®, in Australia, marking a significant step in the company’s global expansion. This follows the product’s approval by the Australian Therapeutic Goods Administration (TGA) and its recent unveiling at the “Aesthetics 2024” event in Sydney. The entry into the Australian market builds on NUCEIVA®’s existing presence in North America, South America, Europe, and Asia.
Evolus, Daewoong’s global partner, played a pivotal role in the Australian debut, hosting a symposium at the event that attracted over 200 medical professionals. The launch comes amid rising interest in non-surgical aesthetic procedures, particularly among younger Australians, positioning NUCEIVA® as a new option for local practitioners seeking to meet evolving patient demands.
Daewoong Pharmaceutical’s CEO, Park Sung-soo, emphasized that the Australian market represents a strategic opportunity for further growth. The company aims to leverage the quality of its product and Evolus’s targeted marketing efforts to build a strong foothold in the region. Evolus plans to support this growth by increasing awareness through training and seminars for medical professionals, enhancing the product’s adoption across Australia.
